Transthyretin Amyloid Cardiomyopathy Latest Advances
Find the Latest Research About Transthyretin Amyloid Cardiomyopathy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 850 publications
10 Things Cardiologists Need to Know About Cardiac Amyloidosis
Journal: Praxis
Published: September 08, 2026
Sodium-glucose cotransporter-2 inhibitor therapy and body composition analysis in transthyretin amyloid cardiomyopathy: a prospective, feasibility pilot study.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: September 08, 2026
Rethinking Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy.
Journal: JAMA cardiology
Published: August 31, 2026
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial.
Journal: Journal of the American Heart Association
Published: August 31, 2026
Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy.
Journal: JAMA cardiology
Published: August 31, 2026
Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.
Journal: JAMA
Published: August 30, 2026
From Static Staging to Dynamic Risk Prediction in Transthyretin Amyloid Cardiomyopathy.
Journal: JAMA cardiology
Published: August 28, 2026
Eplontersen for Transthyretin Amyloid Cardiomyopathy.
Journal: The New England journal of medicine
Published: August 28, 2026
Machine Learning-Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy.
Journal: JAMA cardiology
Published: August 28, 2026
When Perugini grade 3 99mTc-DPD uptake does not indicate transthyretin amyloid cardiomyopathy: a mass spectrometry-confirmed case of AL cardiac amyloidosis.
Journal: Polish archives of internal medicine
Published: August 20, 2026
Last Updated: 09/26/2026